This index evaluates top 50 pharma firms on AI execution, innovation, and talent. Merck shines with a score of 70.7, driven by its "AI-powered business" strategy: deploying internal LLMs across units, leveraging end-to-end AIDD solutions, and boosting efficiency while cutting costs.
In AI innovation, Merck partners with 21 AI firms (including BenevolentAI and Exscientia) to accelerate drug development in oncology, neuroscience, and immunology. It also ranks 2nd globally with 10 AI investments, such as €1.5 billion in German R&D facilities and a $70 million AI materials center in Japan.
Beyond global excellence, Merck China is advancing AI-driven digital strategies to enhance patient outcomes:
🔹 Smart Manufacturing: Nantong site optimizes production/supply chains via AI, with SAP, MES, LIMS, and fully automated logistics (AGV/ASRS), serving 200+ distributors.
🔹 Sales & Access: Collaborations with Alibaba Health, Ping An Good Doctor, and JD.com boost access to chronic disease meds and management knowledge.
🔹 Patient Care: 2023 saw a colorectal cancer AI chatbot on WeChat for precise patient education, plus disease awareness campaigns on Douyin and Bilibili using popular formats like talk shows and rap.
🔹 Empowering HCPs: Digital MSL platform and AI-driven targeted content delivery meet healthcare professionals' academic needs.
🔹 Operational Efficiency: Tools like MyGPT and AI4BI speed up approvals and generate data insights, all while adhering to data security regulations
